CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden and internationally.
Flawless balance sheet with high growth potential.
Share Price & News
How has CellaVision's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CEVI's share price has been volatile over the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: CEVI underperformed the Swedish Medical Equipment industry which returned 17.3% over the past year.
Return vs Market: CEVI exceeded the Swedish Market which returned -9.8% over the past year.
Price Volatility Vs. Market
How volatile is CellaVision's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StWhy CellaVision AB (publ) (STO:CEVI) Looks Like A Quality Company
1 year ago | Simply Wall StWhat Should You Know About CellaVision AB (publ)'s (STO:CEVI) Capital Returns?
1 year ago | Simply Wall StShould You Be Impressed By CellaVision AB (publ)'s (STO:CEVI) ROE?
Is CellaVision undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CEVI (SEK272) is trading below our estimate of fair value (SEK296.74)
Significantly Below Fair Value: CEVI is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CEVI is poor value based on its PE Ratio (65.4x) compared to the Medical Equipment industry average (51.5x).
PE vs Market: CEVI is poor value based on its PE Ratio (65.4x) compared to the Swedish market (15x).
Price to Earnings Growth Ratio
PEG Ratio: CEVI is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: CEVI is overvalued based on its PB Ratio (18.6x) compared to the SE Medical Equipment industry average (3.8x).
How is CellaVision forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CEVI's forecast earnings growth (23.8% per year) is above the savings rate (-0.4%).
Earnings vs Market: CEVI's earnings (23.8% per year) are forecast to grow faster than the Swedish market (8.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CEVI's revenue (15.1% per year) is forecast to grow faster than the Swedish market (4.2% per year).
High Growth Revenue: CEVI's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CEVI's Return on Equity is forecast to be high in 3 years time (31.7%)
How has CellaVision performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CEVI has high quality earnings.
Growing Profit Margin: CEVI's current net profit margins (21.5%) are lower than last year (24.3%).
Past Earnings Growth Analysis
Earnings Trend: CEVI's earnings have grown by 19.9% per year over the past 5 years.
Accelerating Growth: CEVI's earnings growth over the past year (11.8%) is below its 5-year average (19.9% per year).
Earnings vs Industry: CEVI earnings growth over the past year (11.8%) underperformed the Medical Equipment industry 12.6%.
Return on Equity
High ROE: CEVI's Return on Equity (28.5%) is considered high.
How is CellaVision's financial position?
Financial Position Analysis
Short Term Liabilities: CEVI's short term assets (SEK265.3M) exceed its short term liabilities (SEK125.9M).
Long Term Liabilities: CEVI's short term assets (SEK265.3M) exceed its long term liabilities (SEK167.5M).
Debt to Equity History and Analysis
Debt Level: CEVI is debt free.
Reducing Debt: CEVI had no debt 5 years ago.
Debt Coverage: CEVI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CEVI has no debt, therefore coverage of interest payments is not a concern.
What is CellaVision's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CEVI's dividend (0.55%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (2.07%).
High Dividend: CEVI's dividend (0.55%) is low compared to the top 25% of dividend payers in the Swedish market (6.02%).
Stability and Growth of Payments
Stable Dividend: CEVI is not paying a notable dividend for the Swedish market, therefore no need to check if payments are stable.
Growing Dividend: CEVI is not paying a notable dividend for the Swedish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CEVI is not paying a notable dividend for the Swedish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CEVI's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Zlatko Rihter (49yo)
Mr. Zlatko Rihter has been the Chief Executive Officer and President of CellaVision AB since January 1, 2015. Mr. Rihter joined CellaVision in 2015. He served as an Executive Vice President of Global Sales ...
|Founder & Director||26.25yrs||kr193.00k||9.71% SEK582.2m|
|Independent Director||10yrs||kr207.00k||no data|
|Chairman of the Board||4.25yrs||kr494.00k||0.18% SEK10.8m|
|Independent Director||4.92yrs||kr213.00k||no data|
|Independent Director||6.25yrs||kr227.00k||0.037% SEK2.2m|
|Independent Director||1.92yrs||kr133.00k||no data|
|Independent Director||1.92yrs||kr133.00k||no data|
Experienced Board: CEVI's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
CellaVision AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: CellaVision AB (publ)
- Ticker: CEVI
- Exchange: OM
- Founded: 1994
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr5.996b
- Shares outstanding: 23.85m
- Website: https://www.cellavision.com
Number of Employees
- CellaVision AB (publ)
- Mobilvägen 12
- Skåne County
- 223 62
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CEVI||OM (OMX Nordic Exchange Stockholm)||Yes||Registered Shares||SE||SEK||May 2007|
|CLVS.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||May 2007|
|0MR5||LSE (London Stock Exchange)||Yes||Registered Shares||GB||SEK||May 2007|
|CEVIS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Registered Shares||GB||SEK||May 2007|
|C26||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||May 2007|
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden and internationally. It offers analyzers, supplementary software, and peripheral equipment for digital microscopy in the sub-field of hematology. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations. It also offers CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Body Fluid Application, which enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software that removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Proficiency Software, the cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; and CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library of cell morphology. The company sells its products to hospital and commercial laboratories. CellaVision AB (publ) was founded in 1994 and is headquartered in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 22:05|
|End of Day Share Price||2020/04/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.